Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates.
- 12.10.2021, 10:30
- Kategoria: Biznes i finanse
- Źródło: APA-OTS